Microbiologics Inc recalls KWIK-STIK and LYFO DISK, quality control kit for culture media Catalog # 0805K…
The stated reason: Affected products contain Staphylococcus epidermidis instead of the expected Brevundimonas diminuta.
Microbiologics Inc began a medical device recall on June 17, 2025 whose reported distribution included Ohio. FDA
What the record shows
This may cause the user's quality control to fail and delayed diagnosis for the patient. FDA graded it Class II — use may cause temporary or medically reversible health consequences. Quantity affected: 21 total. The recall is listed as ongoing. FDA
Context
By the numbers
- Date of record: June 17, 2025 FDA
- Recall number: Z-2124-2025 FDA
- Recalls in this action: 1 FDA
- Recalling firm: Microbiologics Inc FDA
- Product: KWIK-STIK and LYFO DISK, quality control kit for culture media Catalog # 0805K and 0805L FDA
- Reason for recall: Affected products contain Staphylococcus epidermidis instead of the expected Brevundimonas diminuta. This may cause… FDA
Assembled mechanically from the source filing and The Lantern's own record database — no AI-written prose. Every figure above appears verbatim in the cited record, which is linked on this page. FDA
Sources
The source filing
| Recall number | Z-2124-2025 |
|---|---|
| Recalls in this action | 1 |
| Recalling firm | Microbiologics Inc |
| Product | KWIK-STIK and LYFO DISK, quality control kit for culture media Catalog # 0805K and 0805L |
| Reason for recall | Affected products contain Staphylococcus epidermidis instead of the expected Brevundimonas diminuta. This may cause the user's quality control to fail and delayed diagnosis for the patient. |
| Classification | Class II — use may cause temporary or medically reversible health consequences |
| Recall type | medical device |
| Quantity | 21 total |
| Status | Ongoing |
| Voluntary or mandated | Voluntary: Firm initiated |
| Initiated | 20250617 |
| Reported | 20250723 |
| Distribution | US distribution to states of: Utah and Ohio; and OUS (International) to countries of: Italy, Netherlands, Argentina, Korea, Jordan, Spain, and Bangladesh. |
| Firm location | Saint Cloud, MN, United States |
Published by U.S. Food and Drug Administration (openFDA). This is the agency's public filing as The Lantern received it, shown with its fields named in plain English.